Ovoca Bio (OVXA) H1 2024 earnings summary

Executive summary

• Interim results for the six months ended 30 June 2024 show continued operating losses and a focus on exploring strategic alternatives, including potential M&A or business restructuring.

Financial highlights

• Loss for the period from continuing operations was €1.24 million, compared to €2.37 million for the same period last year.

• Total comprehensive loss for the period was €2.58 million, down from €5.80 million year-over-year.

• Cash and cash equivalents at period end were €2.93 million, down from €3.34 million at year-end 2023.

• Net cash used in operating activities was €1.39 million, compared to €0.68 million in the prior year period.

Outlook and guidance

• Management is not pursuing immediate development of Orenetide and is actively seeking alternative business opportunities, including licensing, sale, or M&A.

• Strategic reviews and discussions are ongoing to realize shareholder value.